Zacks Small Cap Research – REVB Starts 2025 With Bright Future Ahead – Go Health Pro

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl … Read more

Zacks Small Cap Research – CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial… – Go Health Pro

By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Collaboration Agreement with Abbott for Phase 3 TECH-LVAD Trial On March 4, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a collaboration agreement with Abbott for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. In August 2024, Cadrenal … Read more

Zacks Small Cap Research – QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease – Go Health Pro

Zacks Small Cap Research – QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease – Go Health Pro

By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments for rare and orphan diseases, initially in the dermatology space. The company is advancing clinical studies to evaluate lead asset QRX003 for the treatment of Netherton … Read more

Zacks Small Cap Research – EDSA: Raises $15 Million to Advance EB06… – Go Health Pro

Zacks Small Cap Research – EDSA: Raises  Million to Advance EB06… – Go Health Pro

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, … Read more

Zacks Small Cap Research – OMH: Backdrop of Industry Fundamentals, Positive Implications – Go Health Pro

Zacks Small Cap Research – OMH: Backdrop of Industry Fundamentals, Positive Implications – Go Health Pro

By M. Marin NASDAQ:OMH READ THE FULL OMH RESEARCH REPORT HDB sales volume up in 2024 … Ohmyhome Ltd (NASDAQ:OMH), a Singapore-based technology company that operates an online real estate platform, has experienced substantial momentum, reflecting the ongoing strength of the domestic property market and its growth initiatives. For example, resale prices and volume sales … Read more

x